ID   LoVo-MEK-R
AC   CVCL_V402
DR   cancercelllines; CVCL_V402
DR   Cosmic; 1927245
DR   Wikidata; Q54902903
RX   PubMed=22402123;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0399 ! LoVo
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 17
//
RX   PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010;
RA   Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P.,
RA   Haverty P.M., Soriano R., Forrest W.F., Heldens S., Chen H.-F., Toy K.,
RA   Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M.,
RA   Moffat J., Belvin M.P., Lackner M.R.;
RT   "ERK inhibition overcomes acquired resistance to MEK inhibitors.";
RL   Mol. Cancer Ther. 11:1143-1154(2012).
//